Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Published Jul 27, 2016
88 pages — Published Jul 27, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016, provides an overview of the Alnylam Pharmaceuticals, Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
- The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Alnylam Pharmaceuticals, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Alnylam Pharmaceuticals, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Alnylam Pharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potentia

  
Source:
Document ID
GMDHC08097CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Alnylam Pharmaceuticals, Inc. Snapshot61
  Alnylam Pharmaceuticals, Inc. Overview61
  Key Information61
  Key Facts61
Alnylam Pharmaceuticals, Inc. Research and Development Overview73
  Key Therapeutic Areas73
Alnylam Pharmaceuticals, Inc. Pipeline Review104
  Pipeline Products by Stage of Development101
  Pipeline Products Monotherapy111
  Pipeline Products Partnered Products121
    Partnered Products/Combination Treatment Modalities131
Alnylam Pharmaceuticals, Inc. Pipeline Products Glance145
  Alnylam Pharmaceuticals, Inc. Late Stage Pipeline Products141
    Phase III Products/Combination Treatment Modalities141
  Alnylam Pharmaceuticals, Inc. Clinical Stage Pipeline Products151
    Phase II Products/Combination Treatment Modalities151
    Phase I Products/Combination Treatment Modalities161
  Alnylam Pharmaceuticals, Inc. Early Stage Pipeline Products171
    Preclinical Products/Combination Treatment Modalities171
    Discovery Products/Combination Treatment Modalities181
Alnylam Pharmaceuticals, Inc. Drug Profiles1930
  patisiran191
    Product Description191
    Mechanism of Action191
    R&D Progress191
  revusiran201
    Product Description201
    Mechanism of Action201
    R&D Progress203
  ALN-PCSsc231
    Product Description231
    Mechanism of Action231
    R&D Progress232
  fitusiran251
    Product Description251
    Mechanism of Action251
    R&D Progress251
  ALN-AAT261
    Product Description261
    Mechanism of Action261
    R&D Progress261
  ALN-CC5271
    Product Description271
    Mechanism of Action271
    R&D Progress272
  ALN-GO1291
    Product Description291
    Mechanism of Action291
    R&D Progress292
  ALN-HBV311
    Product Description311
    Mechanism of Action311
    R&D Progress312
  ALN-AS1331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  ALN-TTRsc02341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  ALN-VSP351
    Product Description351
    Mechanism of Action351
    R&D Progress352
  ALN-AC3371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  ALN-AGT381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  ALN-ANG391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  ALN-PDL401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  ALN-TMP411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  Cellular Immunotherapy for Oncology and Viral Infections431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  ALN-HDV441
    Product Description441
    Mechanism of Action441
    R&D Progress441
  RNAi Oligonucleotide for Undisclosed Indication451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  RNAi Oligonucleotides for Genetic Diseases461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  RNAi Oligonucleotides for Hepatic Infections471
    Product Description471
    Mechanism of Action471
    R&D Progress471
  RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders481
    Product Description481
    Mechanism of Action481
    R&D Progress481
Alnylam Pharmaceuticals, Inc. Pipeline Analysis496
  Alnylam Pharmaceuticals, Inc. Pipeline Products by Target492
  Alnylam Pharmaceuticals, Inc. Pipeline Products by Route of Administration511
  Alnylam Pharmaceuticals, Inc. Pipeline Products by Molecule Type521
  Alnylam Pharmaceuticals, Inc. Pipeline Products by Mechanism of Action532
Alnylam Pharmaceuticals, Inc. Recent Pipeline Updates5528
Alnylam Pharmaceuticals, Inc. Dormant Projects831
Alnylam Pharmaceuticals, Inc. Company Statement842
Alnylam Pharmaceuticals, Inc. Locations And Subsidiaries861
  Head Office861
  Other Locations &Subsidiaries861
Appendix872
  Methodology871
  Coverage871
  Secondary Research871
  Primary Research871
  Expert Panel Validation871
  Contact Us871
  Disclaimer881

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alnylam-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16205>
  
APA:
Global Markets Direct - Market Research. (2016). Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alnylam-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16205>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.